Natera Inc (NTRA) Stock Analysis
Verdict: HOLD
Oncology-led revenue growth and FCF pivot justify a premium, but aggressive insider selling and 52-week highs signal a tactical pause.
Investment score: 62/100
Analysis as of
Is Natera Inc stock worth reviewing? The TradeMates thesis
Natera is a high-growth diagnostics leader successfully pivoting to profitability, but current valuation and insider signals suggest short-term cooling.
7-factor investment score
- Valuation: 35/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 80/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 50/100 (weight 15%)
Natera Inc opportunities and risks
What speaks for NTRA
- Transition to Free Cash Flow Positivity
What speaks against NTRA
- Aggressive Insider Liquidation
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| NTRA | n/a | 17.0x | n/a | 65.3% | -7.1% | 0.2% |
| AMGN | 25.3x | 5.8x | 16.1x | 72.7% | 22.9% | 4.6% |
| GILD | n/a | 5.4x | 258.8x | 79.6% | -10.6% | 8.0% |
| VRTX | 28.6x | 10.0x | 22.0x | 86.0% | 34.9% | 3.0% |
| REGN | 18.7x | 5.2x | 14.3x | 84.9% | 27.9% | 4.4% |
| Peer median | 22.0x | 5.6x | 19.0x | 82.2% | 25.4% | 4.5% |
Frequently asked questions about Natera Inc (NTRA)
Is NTRA stock a good investment?
The TradeMates model rates Natera Inc as HOLD with an investment score of 62/100. Natera is a high-growth diagnostics leader successfully pivoting to profitability, but current valuation and insider signals suggest short-term cooling. This is algorithmic model output, not personal investment advice.
Is NTRA stock a buy?
The TradeMates model verdict for NTRA is HOLD with an investment score of 62/100. Treat this as a model signal to review, not a personal buy recommendation.